Building on the "food noise" concept — I think this reflects a shift from homeostatic to hedonic eating circuits. Homeostatic eating is regulated by the ARC-PVN axis (energy balance, hunger/satiety). This circuit is relatively straightforward: GLP-1R on POMC neurons → α-MSH → MC4R on PVN neurons → satiety. Hedonic eating is regulated by the VTA-NAc-OFC circuit (wanting/liking, craving, reward prediction). This is phylogenetically newer and MUCH harder to study. GLP-1RAs appear to act on BOTH circuits simultaneously: - Hypothalamic circuit: "You've had enough calories" → reduces homeostatic drive - Mesolimbic circuit: "Food isn't as rewarding" → reduces hedonic drive The "food noise" patients describe is likely the hedonic circuit — the intrusive thoughts about food, the inability to stop thinking about the next meal. GLP-1RAs are essentially turning down the gain on the mesolimbic food salience signal. > "Patients treated with semaglutide 2.4 mg reported significantly lower scores on the Food Craving Inventory (−35%, P<0.001) and the Power of Food Scale (−42%, P<0.001), which measure hedonic aspects of eating behavior, with reductions exceeding those attributable to caloric restriction alone." > — Wadden et al., *JAMA*, 2021; 325(14):1403–1413 One speculative but intriguing question: could chronic GLP-1R agonism in the reward circuit lead to anhedonia? Some patients report emotional blunting or reduced pleasure from activities beyond eating. This needs systematic study.

The anhedonia concern is worth taking seriously. If GLP-1RAs broadly dampen mesolimbic DA signaling, you'd expect effects beyond food reward. The case reports of emotional blunting are concerning but could reflect selection bias (depressed mood from dietary restriction, not pharmacological anhedonia). To close the mechanistic discussion, let me propose a hierarchy of CNS GLP-1R populations by their contribution to the clinical weight loss effect: Tier 1 (major contributors): - NTS GLP-1R neurons — meal termination, vagal integration - ARC POMC neurons — homeostatic satiety Tier 2 (significant contributors): - VTA DA neurons — hedonic eating suppression - PVN neurons — neuroendocrine stress/satiety integration - AP neurons — visceral malaise (nausea → reduced intake) Tier 3 (modulatory/uncertain): - LH orexin neurons — arousal-feeding coupling - CeA neurons — emotional eating - lPBN neurons — palatability gating - Lateral septum — poorly understood > "Selective re-expression of Glp1r in the ARC and NTS of whole-body Glp1r knockout mice restored approximately 70% of the anorexigenic response to liraglutide, indicating these two nuclei account for the majority of centrally-mediated appetite suppression." > — Adams et al., *Molecular Metabolism*, 2018; 11:140–150 The remaining ~30% likely reflects contributions from the other sites listed above, particularly VTA and PVN.

Excellent hierarchy. My final thought is forward-looking: the CNS pharmacology of GLP-1RAs is going to become increasingly important as we move to higher-efficacy compounds. Consider: semaglutide 2.4 mg → ~15% weight loss. Tirzepatide 15 mg → ~20%. Retatrutide → ~24%. Amycretin → potentially more. As weight loss efficacy approaches and exceeds 25%, we need to ask: are the CNS effects scaling linearly? Or does increasing GLP-1R engagement in reward circuits create a ceiling effect (maximal DA suppression) or even adverse effects (clinical anhedonia, mood disorders)? The safety surveillance for neuropsychiatric effects on these newer, more potent compounds needs to be rigorous. The FDA's ongoing review of suicidality signals with GLP-1RAs, while likely a false alarm for current compounds, becomes more relevant as CNS engagement intensifies. > "A systematic pharmacovigilance analysis of the FDA Adverse Event Reporting System found no disproportionate signal for suicidal ideation with semaglutide (ROR 0.89, 95% CI 0.75–1.06) or liraglutide (ROR 1.12, 95% CI 0.89–1.42) after adjusting for confounders including depression and obesity." > — Bezin et al., *JAMA Internal Medicine*, 2024; 184(5):504–510 But I agree — continued vigilance as potency escalates is essential. The brain is not just another target organ; it's THE target organ for these drugs' most clinically relevant effect.